FDA Hormone Therapy Decision Could Have Implications Beyond Hot Flashes

FDA Hormone Therapy Decision Could Have Implications Beyond Hot Flashes

The FDA’s recent decision to remove the boxed warning from menopausal hormone therapy products has generated significant discussion about symptom management during menopause. But according to a new commentary from George Washington University dermatologist Emily Nadelmann, the decision may also prompt renewed conversations about an often-overlooked area: skin health. Nadelmann explains how declining estrogen levels contribute to skin thinning, r…